Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 4,491,078 shares, an increase of 9.2% from the January 12th total of 4,112,919 shares. Based on an average daily trading volume, of 236,822 shares, the short-interest ratio is presently 19.0 days. Approximately 2.9% of the shares of the company are short sold.

Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) opened at $0.35 on Wednesday. Navidea Biopharmaceuticals has a 1-year low of $0.31 and a 1-year high of $0.85. The company has a market capitalization of $57.96, a P/E ratio of -4.86 and a beta of -0.76.

An institutional investor recently raised its position in Navidea Biopharmaceuticals stock. Virtu KCG Holdings LLC grew its position in shares of Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) by 305.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 336,414 shares of the biopharmaceutical company’s stock after buying an additional 253,471 shares during the period. Virtu KCG Holdings LLC owned about 0.21% of Navidea Biopharmaceuticals worth $172,000 as of its most recent SEC filing.

TRADEMARK VIOLATION WARNING: “Navidea Biopharmaceuticals Inc (NAVB) Short Interest Update” was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease.

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with's FREE daily email newsletter.